The Journal of Endocrinological Investigation conducted a study titled Endocannabinoids and the Gastrointestinal Tract, that suggests Cannabinoid Type 1 and 2 receptors are abundant within the GI. This interaction includes protection from inflammatory responses and providing stability to abnormally high gastric and enteric secretions. It has also been outlined that PPARs (Peroxisome proliferator-activated receptors), another receptor site that aids in the expression of anti-inflammatory and homeostasis.
Cannabinoid Type 2 receptors within the Gastrointestinal Tract respond to cannabidiol to aid in the symptoms related to this gluten intolerant disease; common symptoms include nausea, bloating, cramping and tiredness.
Biologically this affects the FAAH (fatty acid amide hydrolase) enzyme that breaks down anandamide (endocannabinoids we naturally produce) by promoting anti-inflammatory effects.
Irritable Bowel Syndrome
Cannabinoids such as CBD demonstrated the ability to block gastrointestinal mechanisms that promote the sensation of pain in IBS. This concept is outlined from the more recently published academic journal, Cannabis and Cannabinoid Research by direct relation to Clinical Endocannabinoid Deficiency. With the use of cannabidiol, it can build up our naturally occurring endocannabinoids such as anandamide (AEA) and 2-Arachidonoylglyerol (2-AG) to bring relief to this distressing condition.